Drug Page

While antidepressants are the most commonly used long-term treatment for depression, the efficacy of these drugs after one year is unknown. In a commentary for The Lancet, psychiatrists Rudolf Uher and Barbara Pavlova suggest that cognitive behavioral therapy (CBT) now has the most substantial body of evidence for long-term treatment for major depressive disorder.

The Scientific American reports on an in-depth reanalysis revealing widespread underreporting of negative side effects, including suicide attempts and aggressive behavior. Article →

Following an extensive systematic review of treatments for major depression, the American College of Physicians (ACP) issued a recommendation to clinicians suggesting cognitive behavioral therapy (CBT) as a first-line treatment for major depressive disorder along with second-generation antidepressants. The results of the review revealed that CBT and antidepressants have similar levels of effectiveness but that antidepressants present serious side-effects and higher relapse rates.

A study published in this month’s issue of the Journal of Clinical Psychiatry found that the use of antidepressant drugs was associated with an...

In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...

Psychologist and Professor Amber Gum has published the story of her personal journey of rethinking psychotropic medication in a special issue on "The Politics of Mental Health" in The Journal of Medicine and the Person. Influenced by Mad in America and the work of Robert Whitaker, Gum became aware of evidence that “suggests that psychotropic medications are less effective and more harmful than most believe” and now hopes to encourage other mental health professionals and researchers to engage in open-minded, critical self-assessment of standard practices.

A woman in Texas attempted suicide while in the active group of a clinical trial for smoking-cassation drugs Chantix and Zyban, both known to...

Four weeks ago, after I wrote a blog about a study that concluded there was no good evidence that antipsychotics improved long-term outcomes for people diagnosed with schizophrenia, I was cc’d on an email that had been sent to a number of “thought leaders” about what I had written. At least as I read the email, it put me into the usual pigeonhole for critics of psychiatric drugs: I apparently was globally “against” medications, and I had displayed a type of simplistic “categorical” thinking. All of this led to my having an email exchange with Allen Frances, and his laying out, in his opinion, the considerable "collateral damage" my writings had done.

Writing for the Harvard Health Blog, Dr. Nandinia Mani reconsiders the use of antidepressants in teens in light of the reanalysis of Study 329. ...

According to new research by Joanna Moncrieff and Sebastião Viola, mental health problems have become the leading cause of disability claims in the UK. While the overall number of claims for other conditions has decreased by 35%, claims related to “mental disorders” have increased 103% since 1995.

Just last week one person was declared brain dead and five more were hospitalized after taking a psychiatric drug in a clinical trial. Writing for Science, Martin Enserink provides more information about the drug as new details emerge.

The warning label for the antidepressant Cymbalta downplayed the risks of withdrawal effects, according to consumer lawsuits being filed in courts across the country. “An estimated 44% to 78% of people who stop taking Cymbalta (also known as duloxetine) will suffer from withdrawal reactions,” yet the warning label “suggests the risk is greater than or equal to 1%.”

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), authored an editorial for BMJ this month warning that the opioid abuse epidemic could have dangerous consequences for pregnant women. While the effects of opioid exposure on the developing brain are yet unknown, research suggests that infants may suffer from withdrawal syndrome, nervous system defects, and impaired attachment with the mother.

“The rising death rates for those young white adults, ages 25 to 34, make them the first generation since the Vietnam War years of the mid-1960s to experience higher death rates in early adulthood than the generation that preceded it,” the ‘Times reports.

A study published this week in the Annals of Family Medicine reveals that opioid painkillers, when used long-term, can lead to the onset of depression. The researchers found that the link was independent of the contribution of pain to depression.

Six men were hospitalized and one was pronounced brain dead after participating in a phase 1 clinical drug for a mood, anxiety, and motor dysfunction drug manufactured by Bial and administered by Biotrial. Carl Elliott, a bioethicist at the University of Minnesota, said investigators should look into questions like how much the men were paid and whether they properly consented to the trial. “Many Phase 1 trial volunteers are poor and unemployed, and they volunteer for trials like this because they are desperate for money,” he said. “This means they are easily exploited.”

Wendy Dolin sued GSK after her husband committed suicide after taking a generic version of Paxil. The US District Court has declined GSK’s motions...

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

The official voice of the American Psychiatric Association covers the short and long term side-effects of antipsychotics and promotes the use of therapeutic alternatives...

On Monday, the US Supreme Court declined to hear Johnson and Johnson’s final appeal, forcing the company to pay $124 million for the deceptive marketing of the antipsychotic Risperdal. In 2011, South Carolina ordered the company to pay $327 million for pursuing “profits-at-all-costs” in its efforts to persuade doctors to prescribe their drug, but the fine was lowered to $136 million last year. The company had hoped to argue that the remaining penalties constituted an “excessive fine” and was supported by PhRMA, the Washington Legal Foundation, the Cato Institute and the Chamber of Commerce.

“A little background digging revealed to me that this study is the tip of a new iceberg relative to ADHD diagnosis, stimulant treatment, and...

“Do they make people less aggressive? Yes, sometimes they do. Will they sedate people? Absolutely. Will they make kids easier to manage? They will,” Robert Whitaker tells Liz Spikol for Philadelphia Magazine. “But I know of no study that shows that medicating these kids long-term will help them grow up and thrive. The developing brain is a very delicate thing. The narrative is that these side effects are mild, and that’s just not true, and that the benefits are well-established, and so often they’re not.”

According to the CDC, January is National Birth Defects Prevention Month. New research continues to link various SSRI antidepressants with birth defects and neurological abnormalities in newborns. The latest study to examine this topic, a meta-analysis led by Dr. Anick Bérard, found a 23% increased risk for birth defects, and a 28% increased risk for heart problems, in the infants of women who took the SSRI Paxil (paroxetine) during their first trimester.

On his website, Dr. Nardo details the hidden risks and bad science behind the growing practice of using atypical antipsychotics to augment antidepressant treatment for severe depression. The story of Atypical Antipsychotic Augmentation of Treatment Resistant Depression is a “prime example” “to illustrate how commercial interests have invaded medical practice.” “Besides the obvious dangers of the Metabolic Syndrome and Tardive Dyskinesia, these drugs don’t really do what they’re advertised to do – make the antidepressants work a lot better.”

Stimulant medications like Ritalin and Adderall, often prescribed to treat children diagnosed with ADHD, are known to cause hallucinations and psychotic symptoms. Until recently these adverse effects were considered to be rare. A new study to be published in the January issue of Pediatrics challenges this belief, however, and finds that many more children may be experiencing psychotic symptoms as a result of these drugs than previously acknowledged.